Date: 2015-06-16
Type of information: Product acquisition
Compound: FibroTrap sample processing technology
Company: Debiopharm (Switzerland) Spinomix (Switzerland)
Therapeutic area: Technology - Services
Type agreement: product acquisition
Action mechanism:
Disease:
Details: * On June 16, 2015, Debiopharm International and Spinomix, a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector, announced the acquisition by Debiopharm of Spinomix\' FibroTrap sample processing technology. FibroTrap is a fibrinogen-based technology allowing the highly specific separation and efficient concentration of target molecules from liquid samples within a simple, routine sample-collection tube. This technology greatly simplifies the sample processing workflow, improves sensitivity and significantly shortens the time taken from sample collection to delivery of results. FibroTrap is applicable to a wide variety of matrices (blood, urine, swabs, food, etc.) to isolate a large spectrum of targets (bacteria, viruses, tumor cells, etc.) and hence could provide a breakthrough in sample processing applied to clinical diagnostics and the food industry.
Financial terms: Commercial terms of the transaction were not disclosed.
Latest news:
